Rocket Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

Rocket Pharmaceuticals Inc faces competition from several companies in the market. Some of its main competitors include bluebird bio, CRISPR Therapeutics, Novartis AG, Editas Medicine, and Sangamo Therapeutics. These companies are also actively involved in the research and development of gene therapies and genetic medicines, making them direct competitors to Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals Inc, founded in 2015, is a promising biotechnology company focused on the development of cutting-edge gene therapies. Headquartered in New York, Rocket Pharma is dedicated to providing innovative treatments for rare childhood genetic disorders. The company's mission is to transform patients' lives by leveraging its proprietary targeted ex vivo lentiviral vector (TRLV) platform to develop potential curative therapies. With a strong foundation in gene therapy expertise, Rocket Pharma collaborates with leading academic institutions and industry partners to advance its pipeline of potential life-changing treatments. Rocket Pharmaceuticals Inc is committed to improving patients' lives through pioneering genetic medicine.

Rocket Pharmaceuticals Inc has achieved several significant milestones. Firstly, the company successfully completed a Phase 1/2 clinical trial for their lead gene therapy candidate, RP-L102, in patients with Fanconi anemia. Furthermore, they received FDA Fast Track designation for RP-L102, recognizing the urgent need for a treatment for this rare genetic disorder. In addition, Rocket Pharmaceuticals Inc entered into a research collaboration with Dana-Farber Cancer Institute to develop innovative gene therapies for rare pediatric diseases. These achievements highlight the company's commitment to advancing gene-based therapies for devastating diseases and underscores their potential to revolutionize the field of genetic medicine.

Rocket Pharmaceuticals Inc is primarily present in the United States. They are a leading biotechnology company that focuses on the development of gene therapies for rare and devastating diseases. As a US-based company, Rocket Pharmaceuticals Inc operates in various regions across the country, including major states like California, Massachusetts, and New York. With their innovative therapies and cutting-edge research, Rocket Pharmaceuticals Inc is dedicated to improving the lives of patients globally, while also making significant contributions to the advancement of gene therapy treatments within the United States.

Rocket Pharmaceuticals Inc represents a strong emphasis on scientific innovation, patient-focused care, and ethical business practices. As a leading biotechnology company, Rocket Pharmaceuticals is committed to developing and commercializing transformative gene therapies for those suffering from rare genetic diseases. With a corporate philosophy centered around the pursuit of breakthrough treatments and improving the lives of patients and their families, Rocket Pharmaceuticals strives for excellence in research, collaboration, and regulatory compliance. By leveraging cutting-edge genetic technologies and collaborating with key industry stakeholders, Rocket Pharmaceuticals aims to provide hope and new possibilities for individuals with rare diseases.

Analysts currently set an average price target of 7.86 USD for the Rocket Pharmaceuticals stock (median: 8.16 USD), implying +126.6 % versus the latest price. The consensus is based on 21 analyst ratings.

Rocket Pharmaceuticals Analyst Price Targets 2026

21 analysts currently rate the Rocket Pharmaceuticals stock: 12 recommend buying, 7 holding and 2 selling. For 2026, analysts expect Rocket Pharmaceuticals to generate revenue of 985,670.00 USD and earnings per share of -0.10 USD.

Rocket Pharmaceuticals Analyst Price Targets 2026

Converted at the current exchange rate, the Rocket Pharmaceuticals share trades at 3.00 EUR (3.47 USD).

The Rocket Pharmaceuticals share (RCKT) is listed on 4 stock exchanges, including: NASDAQ (RCKT), Frankfurt (9IP1.F), München (9IP1.MU), Düsseldorf (9IP1.DU).

The company Rocket Pharmaceuticals Inc focuses on innovative gene and cell therapy for the treatment of serious genetic diseases. The company specializes in the development, manufacturing, and marketing of gene therapies. Rocket Pharmaceuticals' business model is based on various areas that all aim to improve the quality of life for patients. The main areas are research and development, manufacturing, and distribution. In research and development, Rocket Pharmaceuticals focuses on identifying genetic disorders to find and develop new treatment options. The company works closely with academic institutions and clinicians to find the best solutions for patients. The manufacturing of gene therapy products is another important component of Rocket Pharmaceuticals' business model. The company uses advanced technologies and methods to ensure the safe, efficient, and cost-effective production of gene therapy products. The distribution of gene therapy products is another important pillar of the company. Rocket Pharmaceuticals works closely with hospitals and clinicians to ensure that gene therapy products reach the patients who need them most urgently. An important focus of Rocket Pharmaceuticals is the treatment of rare genetic diseases, which are often difficult to diagnose and treat. The company focuses on the development of gene therapies that target the underlying cause of the disease rather than just treating the symptoms. Currently, the company is focusing on developing gene therapies for rare diseases such as Fanconi anemia, leukodystrophies, hemophilia, and mucopolysaccharidosis. Rocket Pharmaceuticals works closely with patients and families to ensure that the gene therapy products meet the needs of patients and their families. Rocket Pharmaceuticals' business model is based on solid research, efficient manufacturing, and targeted distribution of gene therapy products for rare genetic diseases. The company strives to develop better therapies for patients affected by these diseases and seeks to improve the lives of millions of people worldwide.

The expected revenue of Rocket Pharmaceuticals is 985,670.00 USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Rocket Pharmaceuticals is -11.39 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Rocket Pharmaceuticals is currently -33.85. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Rocket Pharmaceuticals stock.

The price-to-sales ratio (P/S) of Rocket Pharmaceuticals is currently 391.21. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Rocket Pharmaceuticals stock.

The Eulerpool Quality Score for Rocket Pharmaceuticals is 2/10.

The ISIN of Rocket Pharmaceuticals is US77313F1066. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Rocket Pharmaceuticals is A2JA9Q. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Rocket Pharmaceuticals is RCKT. The ticker symbol is used to trade Rocket Pharmaceuticals shares on the stock exchange.

Rocket Pharmaceuticals paid dividends every year for the past 0 years.

Rocket Pharmaceuticals is assigned to the 'Health' sector.

The dividends of Rocket Pharmaceuticals are distributed in USD.